Esperion Therapeutics | ESPR - Operating Expenses

Stock Price
3.49
Daily Change
0.10 2.80%
Monthly
-1.83%
Yearly
85.37%
Q1 Forecast
2.70

Esperion Therapeutics reported $67.66M in Operating Expenses for its fiscal quarter ending in September of 2024.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alnylam Pharmaceuticals USD 881.04M 91.16M Sep/2025
Alterity Therapeutics Limited AUD 7.78M 3M Jun/2023
Amarin USD 51.37M 14.6M Sep/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
BioMarin Pharmaceutical USD 807.82M 259.3M Sep/2025
Cipla INR 60.98B 1.06B Dec/2025
CSL USD 2.87B 2.85B Jun/2025
Cytokinetics USD 168.69M 9.58M Sep/2025
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Geron USD 61.11M 376K Sep/2025
Grifols EUR 1.77B 22.04M Sep/2025
Halozyme Therapeutics USD 136.34M 13.06M Sep/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Merck USD 10.16B 558M Dec/2025
Minerva Neurosciences USD 4.52M 155.46K Dec/2024
Moderna USD 1.28B 232M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Pfizer USD 12.91B 79.89B Dec/2025
PTC Therapeutics USD 207.52M 6.21M Sep/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 2.99B 27.97B Dec/2025
Sanofi EUR 10.51B 1.21B Dec/2025
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
United Therapeutics USD 6.59B 6.07B Sep/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025